Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Novartis |
---|---|
Information provided by: | Novartis |
ClinicalTrials.gov Identifier: | NCT00375648 |
This study will evaluate the efficacy and safety of 4 mg zoledronic acid administered intravenously every 3-4 weeks in the treatment of bone metastases-related pain in patients with prostate cancer.
Condition | Intervention | Phase |
---|---|---|
Pain |
Drug: Zoledronic acid |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Assessment of the Efficacy and Safety of Zoledronic Acid in the Treatment of Bone Metastases-Related Pain in Patients With Prostate Cancer |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Other protocol-defined exclusion criteria may apply.
Responsible Party: | Novartis ( External Affairs ) |
Study ID Numbers: | CZOL446EFR08 |
Study First Received: | September 11, 2006 |
Last Updated: | June 30, 2008 |
ClinicalTrials.gov Identifier: | NCT00375648 |
Health Authority: | France: Afssaps - French Health Products Safety Agency |
Prostate Cancer Bone metastases |
Zoledronic acid Bone metastases-related pain Prostate cancer |
Diphosphonates Zoledronic acid Prostatic Diseases Genital Neoplasms, Male Neoplasm Metastasis |
Urogenital Neoplasms Pain Genital Diseases, Male Prostatic Neoplasms |
Neoplasms Neoplastic Processes Neoplasms by Site Pathologic Processes |
Physiological Effects of Drugs Bone Density Conservation Agents Pharmacologic Actions |